NDA 018264 · Ph Health
Dantrium
Dantrolene Sodium · Injection
Priority reviewOrphanLast checked: Nov 19, 2026Latest source record: Apr 2, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1979
Sep 19, 1979
Approved uses
3
Original approval plus efficacy supplements
Registered trials
12
4 Phase 3, 1 recruiting
FAERS reports
1,138
998 serious, 124 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Mar 10, 2026.
INDICATIONS AND USAGE: Dantrium Intravenous is indicated, along with appropriate supportive measures, for the management of the fulminant hypermetabolism of skeletal muscle characteristic of malignant hyperthermia crises in patients of all ages. Dantrium Intravenous should be administered by continuous rapid intravenous push as soon as the malignant hyperthermia reaction is recognized (i.e., tachycardia, tachypnea, central venous desaturation, hypercarbia, metabolic acidosis, skeletal muscle rigidity, increased utilization of anesthesia circuit carbon dioxide absorber, cyanosis and mottling of the skin, and, in many cases, fever). Dantrium Intravenous is also indicated preoperatively, and sometimes postoperatively, to prevent or attenuate the development of clinical and laboratory signs of malignant hyperthermia in individuals judged to be malignant hyperthermia susceptible.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 12, 1987 Supplement 11 · Efficacy
- Feb 26, 1982 Supplement 3 · Efficacy
- Sep 19, 1979 Original approval · Type 3 - New Dosage Form · priority review
1 products under this application
- DANTRIUM · DANTROLENE SODIUM 20MG/VIAL · INJECTABLE, INJECTION · Prescription · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Dantrolene" as an intervention, any sponsor and status, largest first.
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT03109288 · 250 participants (planned) · Start Aug 11, 2017 · Primary completion Jan 1, 2027
Drug: Cilostazol; Leucovorin and 3 more · For: Multiple Sclerosis
Sites: Bethesda, Maryland
- The Use of Dantrolene to Improve Analgesia in Posterior Lumbar SurgeryPivotal-lookingCompleted
Beth Israel Deaconess Medical CenterAcademic, hospital or other
NCT03762109 · 116 participants · Start Jul 29, 2019 · Primary completion Jun 1, 2024
Drug: Dantrolene; Placebo Oral Tablet · For: Lumbar Spine Injury
Sites: Boston, Massachusetts
- A Clinical Trial Utilizing Dantrolene in Patients With Ventricular Arrhythmias.Pivotal-lookingCompleted
Vanderbilt University Medical CenterAcademic, hospital or other
NCT04134845 · 68 participants · Start Aug 21, 2020 · Primary completion May 29, 2025
Drug: Dantrolene/Ryanodex; Placebo · For: Ventricular Tachycardia
Sites: Nashville, Tennessee
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH
NCT01950520 · 47 participants · Start Feb 7, 2014 · Primary completion Dec 17, 2022
Drug: Propranolol; Pindolol and 11 more · For: Healthy Volunteers
Sites: Bethesda, Maryland
- Dantrolene for Treatment of Hyperthermia in Subarachnoidal Hemorrhage (SAH)Pivotal-lookingTerminated
Medical University of ViennaAcademic, hospital or other
NCT00796900 · 34 participants (planned) · Start May 2008 · Primary completion Mar 2011
Drug: Dantrolene; Placebo · For: Hyperthermia
Sites: Vienna, Austria
Eagle Pharmaceuticals, Inc.Industry
NCT02513095 · 34 participants · Start Sep 2015 · Primary completion Sep 2015
Drug: Dantrolene sodium for injectable suspension · For: Heat Stroke
Sites: Mecca, Saudi Arabia
University of Massachusetts, WorcesterAcademic, hospital or other
NCT01024972 · 31 participants · Start Oct 2009 · Primary completion Jul 2013
Drug: Dantrolene; Placebo · For: Subarachnoid Hemorrhage; Cerebral Vasospasm
Sites: Worcester, Massachusetts
- Dantrolene in Statin-induced MyopathyPivotal-lookingNot yet recruiting
Tanta UniversityAcademic, hospital or other
NCT06966843 · 23 participants (planned) · Start Oct 2027 · Primary completion Jan 2029
Drug: Dantrolene; Placebo · For: Statins Induced Myopathy
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- neuroleptic malignant syndrome79
- pyrexia63
- pneumonia61
- asthenia59
- drug ineffective59
- respiratory failure59
- off label use54
- urinary tract infection52
- vomiting52
- diarrhoea49
- muscular weakness45
- nausea45
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 45 |
| 2005 | 47 |
| 2006 | 54 |
| 2007 | 49 |
| 2008 | 59 |
| 2009 | 62 |
| 2010 | 61 |
| 2011 | 81 |
| 2012 | 83 |
| 2013 | 73 |
| 2014 | 43 |
| 2015 | 46 |
| 2016 | 63 |
| 2017 | 57 |
| 2018 | 45 |
| 2019 | 53 |
| 2020 | 42 |
| 2021 | 31 |
| 2022 | 36 |
| 2023 | 35 |
| 2024 | 27 |
| 2025 | 30 |
| 2026 | 16 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Dantrium (Dantrolene Sodium)
2024 spending
$8K
Beneficiaries
n/a
39 claims
Per beneficiary
n/a
$1.02 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $29,516 |
| 2021 | $26,804 |
| 2022 | $17,162 |
| 2023 | $9,844 |
| 2024 | $7,941 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal conditions: a systematic review.
Chou R, Peterson K, Helfand M · J Pain Symptom Manage 2004 · Comparative Study, Evaluation Study
- Anti-spasticity agents for multiple sclerosis.
Shakespeare DT, Boggild M, Young C · Cochrane Database Syst Rev 2001 · Systematic Review
- Anti-spasticity agents for multiple sclerosis.
Shakespeare DT, Young CA, Boggild M · Cochrane Database Syst Rev 2000 · Systematic Review
- Anti-spasticity agents for multiple sclerosis.
Shakespeare DT, Boggild M, Young C · Cochrane Database Syst Rev 2003 · Systematic Review
- Myoplasmic Ca2+ concentration during exertional rhabdomyolysis.
López JR, Rojas B, Gonzalez MA, et al. · Lancet 1995 · Clinical Trial, Controlled Clinical Trial
- The novel rapid formulation of intravenous dantrolene (NPJ5008) versus standard dantrolene (Dantrium®): A clinical part-randomised phase 1 study in healthy volunteers.
Ng Kwet Shing RH, Clayton LB, Smith SL, et al. · Eur J Anaesthesiol 2024 · Randomized Controlled Trial, Clinical Trial, Phase I
Sponsor: Ph Health
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.